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Abstract
Background: Numerous stem cell therapies use injection-based administration to deliver high-density cell
preparations. However, cell retention rates as low as 1% have been observed within days of transplantation.
This study investigated the effects of varying administration and formulation parameters of injection-based
administration on cell dose recovery and differentiation fate choice of human mesenchymal stem cells.
Methods: The impact of ejection rate via clinically relevant Hamilton micro-syringes and biomaterial-assisted
delivery was investigated. Cell viability, the percentage of cell dose delivered as viable cells, proliferation capacity as
well as differentiation behaviour in bipotential media were assessed. Characterisation of the biomaterial-based cell
carriers was also carried out.
Results: A significant improvement of in-vitro dose recovery in cells co-ejected with natural biomaterials was observed,
with ejections within 2% (w/v) gelatin resulting in 87.5 ± 14% of the cell dose being delivered as viable cells, compared
to 32.2 ± 19% of the dose ejected in the commonly used saline vehicle at 10 μl/min. Improvement in cell recovery was
not associated with the rheological properties of biomaterials utilised, as suggested by previous studies. The extent of
osteogenic differentiation was shown to be substantially altered by choice of ejection rate and cell carrier, despite
limited contact time with cells during ejection. Collagen type I and bone-derived extracellular matrix cell carriers
yielded significant increases in mineralised matrix deposited at day 21 relative to PBS.
Conclusions: An enhanced understanding of how administration protocols and biomaterials influence cell recovery,
differentiation capacity and choice of fate will facilitate the development of improved administration and formulation
approaches to achieve higher efficacy in stem cell transplantation.
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Background
To date, most clinical trials employing cell-based thera-
peutics have used injectable delivery of cellular suspen-
sions in saline vehicles [1–3]. However, cell loss has been
observed within the first minutes post injection [4], with
less than 10% of injected cells retained at the site of inter-
est [2, 5]. Consequently, increasing the percentage of vi-
able cells delivered and retained post injection is critical to
the future success of cell transplantation procedures.
Mesenchymal stem cells (MSCs) have been the focus
of numerous pre-clinical and clinical cell therapy studies
[6]. Stem cell fate is regulated by biochemical and bio-
physical cues from the microenvironment [7, 8]. As
such, an intricate range of environmental effectors, expe-
rienced both during the delivery procedure and post
transplantation, can impact cell function [9]. For ex-
ample, cells experience various types of mechanical
forces, including shear forces, during flow through a
needle [10]. Although shear stress has been reported to
directly influence the fate of undifferentiated stem cells
[11, 12], the impact of mechanical forces experienced
during clinically relevant injection procedures upon the
differentiation potential of hMSCs has yet to be
investigated.
Numerous studies have highlighted that the material
surrounding a stem cell is vital in determining its fate
[13–15]. Biomaterials can be used as cell delivery vehi-
cles to provide physical support and protection for cells
and stimulate host cell recruitment and differentiation
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[16]. Naturally derived biomaterials may exhibit inherent
bioactivity that can facilitate tissue integration. Examples
of naturally derived biomaterials include collagen, which
has been shown to support cell growth in 3D cell culture
studies and in vivo [17–21], and tissue-derived extracel-
lular matrices (ECMs), harvested by decellularisation of
mammalian tissues [22]. ECM materials retain the inher-
ent bioactivity of the native matrix and modulate cell be-
haviour and promote constructive remodelling in vivo
[23]. Other natural biomaterials, such as protein-based
polymers, have found utility as cell carriers because
these biomaterials may mimic characteristics of the nat-
ural ECM and influence the growth and fate of trans-
planted cells [24]. An example of naturally derived
biomaterials is carboxymethyl cellulose (CMC), a bio-
degradable polysaccharide-based polymer with excellent
biocompatibility [25, 26].
With the rising number of clinical trials exploring
MSC-based cell therapies, an understanding of the fac-
tors that influence the functionality of cells post injec-
tion is critical. Despite the advantages of biomaterials as
cell transplantation vehicles, saline-based cell carriers
still continue to be the carrier of choice for many cell
therapy clinical trials [1–3]. Since physical, chemical and
biological factors have an impact on differentiation be-
haviour of cells [27], cues caused by variations in cell ad-
ministration protocols can contribute to differentiation
commitment decisions of MSCs. Our previous work
provided evidence that ejection of cell suspensions at a
low flow rate negatively impacted cell dose recovery, via-
bility and function [28, 29]. An enhanced understanding
of how injectable biomaterials improve cell dose recov-
ery and influence stem cell differentiation will facilitate
the development of improved administration and formu-
lation approaches to achieve higher efficacy and reduce
variability in stem cell transplantation. The present study
aimed to examine the influence of varying cell adminis-
tration and formulation parameters on fate choice of
hMSCs by assessing the impact of ejection upon the dif-
ferentiation capacity of primary human MSCs using clin-
ically relevant needles and by determining the potential
value of user-friendly injectable biomaterials to improve
delivery efficiency and to direct cell fate.
Methods
Overall experimental design
The general experimental design for this study is
depicted schematically in Additional file 1: Figure S1.
The first part of this study aimed to determine whether
the initial cell seeding density influenced differentiation
capacity. This was key to understanding whether any im-
pact observed on differentiation capacity would be re-
lated to the number of cells being ejected at the slow
flow rates employed [28] or to the effect of cell
administration variables under investigation. The second
part of the study assessed the impact of varying ejection
rate on the differentiation capacity of ejected cells. Cell
dose recovery and differentiation capacity of hMSCs
ejected within various injectable biomaterial-based car-
riers were examined at low ejection rates. Differentiation
to osteoblastic and adipogenic lineages was examined in
bipotential differentiation ‘mixed’ media, with a formula-
tion designed to induce both.
Human mesenchymal stem cell culture
Primary human bone marrow mesenchymal stem cells
(hMSCs) were obtained from Lonza and cultured in
mesenchymal stem cell growth medium (MSCGM) (#PT-
3001; Lonza, Cologne, Germany) with 5% CO2 in air at
37 °C. Lot numbers of hMSC batches obtained were
#0000351482, #0000411107 and #0000422610, cultured as
individual patient stocks. Cells used in this study were be-
tween the third and fifth passages. These cells were tested
for the ability to differentiate into osteogenic, adipogenic
and chondrogenic lineages, and for expression of surface
markers recommended by the International Society for
Cellular Therapy (ISCT) [30]. All routine passaging and
differentiation procedures were performed according to
Lonza’s Poietics™ hMSC protocols.
Effects of cell seeding density on differentiation potential
of hMSCs
Cell seeding densities tested ranged from 1000 to 70,000
hMSCs per well in 12-well plates (Nunc, Thermo Fisher
Scientific, UK), equivalent to 0.3 × 103–18.4 × 103 cells/
cm2. Twenty-four hours after seeding, the medium was
replaced with bipotential differentiation medium, formu-
lated by combining adipogenic (#PT-3004; Lonza) and
osteogenic (#PT-3002; Lonza) media in a 1:1 ratio. The
culture was incubated for 21 days. The differentiation
medium was changed every 3–4 days for the duration of
the differentiation period. Nuclear-based cell counts
were carried out using propidium iodide (PI) staining of
the fixed cells in osteogenesis experiments and using
Hoechst 33258 in adipogenesis studies.
Preparation of hMSCs and ejection protocol
After trypsinisation, cells were centrifuged and then
reconstituted to a density of 1.4 × 106 cells/ml in phos-
phate buffered saline (PBS) for cell ejection studies, and
then were mixed 1:1 with either PBS or the biomaterial-
based carrier under investigation (via gentle mixing) to a
final density of 7 × 105 cells/ml. Density of cell suspen-
sions used in this study was selected conservatively
based on published clinical studies [31–33] as well as
practical considerations. Aliquots (100 μl) of this cell
suspension were used for ejection experiments. Cells
were directly pipetted into well plates (not ejected) to
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provide controls. For ejection, 100-μl Hamilton GAS-
TIGHT® syringes (model 1710RN) attached to 30G 20-
mm removable (RN) stainless steel needles were
employed (Hamilton Bonaduz, Switzerland). All ejection
studies were carried out at room temperature. Cell/car-
rier mixtures were set aside for 20 min before ejection,
to represent the delay time between loading and injec-
tion in cell transplantation procedures [34]. Ejection
rates employed in clinical trials have been variable,
ranging from 5 μl/min [35] to 1000 μl/min for stroke
[36, 37]. Therefore, ejection rates employed in this study
(10–300 μl/min) were selected to represent a range of
clinically relevant ejection rates used previously in
clinical trials. Cell suspensions were drawn up with a
Harvard® Infuse/Withdraw syringe pump (PHD 2000;
Harvard Apparatus®, MA, USA) at 300 μl/min through
the needle before being ejected at the chosen flow rate
into Eppendorf tubes. Ejected samples were then trans-
ferred into the appropriate well plates.
Qualitative and quantitative assessment of differentiation
capacity of ejected hMSCs
Differentiation to osteoblastic and adipogenic lineages
was examined in bipotential ‘mixed’ media (see ‘Effects
of cell seeding density’). Bipotential medium was added
to the cells in 12-well plates at 24 h post seeding, and
cells were alternated between adipogenic induction/
osteogenic induction media (1:1) and adipogenic main-
tenance/osteogenic media (1:1) every 3–4 days, accord-
ing to the manufacturer’s instructions, for 21 days.
Uninduced controls were maintained in basal medium
MSCGM (#PT-3001; Lonza).
Adipogenic differentiation
After 21 days, cultures were rinsed with 70% (v/v) iso-
propanol for 5 min and differentiation was assessed
qualitatively by specific staining of lipid droplets with
0.5% Oil Red O solution (Sigma-Aldrich, Poole, UK).
Intracellular lipid accumulation was quantified using the
AdipoRed™ Adipogenesis Assay (Lonza) following the
manufacturer’s protocol. Briefly, cells were pre-washed
with PBS and incubated with AdipoRed™ Reagent for
10 min. Fluorescence was measured using a plate reader
(λexc/λem 485/572 nm).
Osteogenic differentiation
After 21 days of incubation, cells were fixed in 10% (v/v)
formalin. The presence of extracellular calcium deposits
was qualitatively verified using Alizarin Red staining so-
lution (Merck Millipore, UK) and von Kossa silver stain-
ing kit (Merck Millipore). For Alizarin Red staining, cells
were treated with Alizarin Red S for 5 min at room
temperature. After washing three times in deionised
water, cells were observed microscopically. For von
Kossa staining, cells were incubated with silver nitrate so-
lution under exposure to UV light for 20 min. Wells were
then washed with deionised water three times, and treated
with sodium thiosulfate solution for 5 min. Afterwards,
wells were washed three times with deionised water.
Mineralised nodules were visualised as black spots.
OsteoImage™ staining for quantitation of hydroxyapatite
deposition In-vitro mineralisation was assessed by stain-
ing the hydroxyapatite portion of mineralised bone nod-
ules using the OsteoImage™ Mineralisation Assay kit
(Lonza) according to the manufacturer’s instructions.
Briefly, cells were fixed in 10% (v/v) formalin, rinsed
twice using the wash buffer, stained with the staining so-
lution provided (1:100 dilution in wash buffer) and incu-
bated for 30 min. Following incubation, cells were rinsed
three times with wash buffer. This assay allows the as-
sessment of in-vitro mineralisation both visually by
fluorescent microscopy and quantitatively using a plate
reader (λexc/λem 492/520 nm).
Quantitative alkaline phosphatase staining For quan-
titative determination of alkaline phosphatase (ALP) ac-
tivity, the Fluorometric Alkaline Phosphatase Assay Kit
(#ab83371; Abcam, UK) was used, as per the manufac-
turer’s protocol. Cultured cells were lysed using three
freeze–thaw cell lysis steps. Samples (media or cell
lysate) were incubated with the non-fluorescent 4-
methylumbelliferyl phosphate disodium salt (MUP) as a
substrate. The resultant fluorescence was measured
using a plate reader. ALP activity was normalised to total
DNA content, measured using the Quant-iT PicoGreen
dsDNA Assay Kit (#P11496; Invitrogen, UK).
Osteocalcin immunostaining hMSCs were rinsed with
warm PBS and fixed with 3.7% (w/v) paraformaldehyde
in PBS for 20 min, followed by a wash with warm PBS
for 5 min. Cells were permeabilised using 0.1% (w/v)
Triton-X 100 in PBS (Sigma-Aldrich) for 30 min. Non-
specific binding sites were blocked by incubation in 10%
(v/v) normal donkey serum (D9663; Sigma-Aldrich) and
1% bovine serum albumin (BSA) in PBS for 1 h. Cells
were then incubated with Mouse Anti-Human Osteocal-
cin Monoclonal Antibody (MAB1419; R&D Systems) di-
luted in 1% (w/v) BSA in PBS at 10 μg/ml for 3 h at
room temperature. This was followed by two washes
with PBS supplemented with 0.1% (w/v) BSA (5 min
each). The secondary antibody, a Donkey Anti-Mouse
IgG-FITC antibody (NL007; R&D Systems), diluted in
1% (w/v) BSA in PBS (1:200) was added for 1 h in the
dark, followed by two washes with PBS (5 min each).
Samples were counterstained with DAPI NucBlue® Fixed
Cell ReadyProbes (ThermoFischer Scientific) for 5 min,
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and then visualised using a Leica DM-IRB inverted
microscope (Leica Microsystems Ltd., UK).
Preparation of biomaterial-based carriers for ejection of
hMSCs
Carboxymethyl cellulose
CMC carriers were prepared using high-viscosity CMC
(#12M31P; Ashland Speciality Ingredients, Poole, UK) in
tissue culture water at concentrations of 0.5% and 0.25%
(w/v). CMC carriers were sterilised by tyndallisation, car-
ried out by heating the prepared solutions three times at
70 °C for 20 min each at 24-h intervals.
Type I collagen
Commercially available high-concentration rat-tail colla-
gen type I (#354249, 10 mg/ml; BD Biosciences, Oxford,
UK) was prepared at a concentration of 1.75 mg/ml fol-
lowing the manufacturer’s instructions. Briefly, collagen
was freshly prepared for experiments by combining rat-
tail collagen type I with 10× PBS, ice-cold 1 N sodium
hydroxide and sterile ice-cold deionised water to achieve
a final collagen concentration of 1.75 mg/ml. The solu-
tion was mixed and kept at 4 °C.
Bone extracellular matrix
Decellularised and demineralised bone extracellular
matrix (bECM) was obtained as described previously [38].
Briefly, liquid nitrogen was used to freeze bovine cancel-
lous bone to facilitate fragmentation. Cancellous frag-
ments were demineralised using 0.5 M HCl at room
temperature for 24 h. Following demineralisation, a solu-
tion of chloroform/methanol was used to remove lipids
and then demineralised powder was subjected to 24 h of
decellularisation in 0.05% Trypsin/0.02% EDTA at 37 °C.
Powdered bone was combined with 1 mg/ml pepsin in
0.01 M HCl for a final concentration of 10 mg/ml and this
suspension was stirred for 96 h. Resultant bECM digests
were aliquoted and stored at − 20 °C until required. Neu-
tralisation of the required digest volume was carried out
by addition of one-tenth of the digest volume of NaOH
(0.1 N) and one-ninth of the digest volume of PBS (10×),
and then diluting to the desired final bECM concentration
with 1× PBS on ice. A concentration of 1.75 mg/ml bECM
was freshly prepared for ejection studies.
Gelatin
Commercially available 2% (w/v) gelatin solution in
water, derived from bovine skin (type B, #G1393; Sigma-
Aldrich), was used for biomaterial-based cell ejection
studies.
Assessing cell recovery and proliferation using PrestoBlue™
Since cell dose recovery results determined using Presto-
Blue™ were shown previously to be comparable to the
DNA-based Cyquant assay for determination of cell num-
bers ejected through Hamilton syringes [28]. PrestoBlue™
(Invitrogen Life Sciences, Paisley, UK) was used to deter-
mine 24-h viability following ejection of cell suspensions
(7 × 105 cells/ml), as well as proliferation over several days.
The PrestoBlue™:culture medium (1:9) mixture was added
to each well, and incubated in the dark at 37 °C for 1 h.
Triplicate 100-μl aliquots were measured for fluorescence
on a Tecan Infinite M200 microplate reader (Tecan,
Reading, UK) at λexc/λem 560/590 nm.
Multiplexing quantitative differentiation assays with
nuclear staining
Multiplexing of cell-specific differentiation assays and
nuclear staining allowed for normalisation to cell num-
ber. After differentiated cells were stained with the
OsteoImage™ Staining Reagent, 100 μg/ml RNase A solu-
tion (AppliChem, Darmstadt, Germany) in Tris–EDTA
buffer solution (Sigma-Aldrich) was added for 10 min at
room temperature. Nuclear staining was carried out using
2 μg/ml PI (diluted in H2O from 1 mg/ml; ThermoFisher
Scientific, UK) for 5 min. For quantitation, the mean
fluorescence intensity of each well was determined using
multiple readings of each well at λexc/λem 490/530 nm for
OsteoImage™ (> 64 readings/well) and 535/617 nm for PI
(100 readings/well). For quantification of adipogenesis,
differentiated cells were stained with AdipoRed™ Assay
Reagent (Lonza). Nuclear staining in adipogenic analysis
was carried out using 2 μg/ml Hoechst 33,258 (diluted in
H2O from 1 mg/ml; Sigma-Aldrich) for 15 min. The mean
fluorescence intensity of each well was determined using
100 readings per well.
Rheological analysis of biomaterial-based carriers
Rheological assessment was carried out with a Physica
MCR301 rheometer (Anton Paar, UK) using rotational
and oscillatory measurements. A 50-mm diameter cone
plate (CP 50–1) was used, except for thixotropy recovery
studies which were performed using a PP 25 parallel plate,
with a 0.2-mm measuring gap. All measurements were
carried out at a controlled temperature of 25 °C. Samples
were allowed to equilibrate for at least 2 min prior to ana-
lysis. A minimum of three independent measurements
were obtained for each sample, and the average value was
reported. Viscosity was determined using a constant shear
rate of 1 s− 1. The average value of all readings at 6-s inter-
vals over a span of 120 s was taken as the viscosity meas-
urement. Steady shear rheology was performed with a
shear rate varying from 0.01 to 1000 s− 1. Viscometric
thixotropy testing was carried out by applying a high-
magnitude strain (10,000 s− 1) to break the biomaterial’s
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structure, followed by a low-level strain (1 s− 1) to observe
the rate and extent of recovery of carrier bulk properties.
Samples were also subjected to oscillatory strain sweeps
from 0.1 to 1000% performed at 6 rad/s to assess the fail-
ure strain for these materials.
Contact angle measurement
Contact angles of the carriers with glass were measured
using the sessile drop method. Soda-lime glass slides
were used for measuring contact angles, which have
similar wettability and surface tension in air to the boro-
silicate glass surfaces of syringes [39]. Contact angles
were measured with a CAM 200 instrument (KSV In-
struments, Finland) after 10-s spreading time. A drop of
the material to be tested was formed on the end of a
precision syringe and placed onto the glass slide. Ten
images of the drop were taken at 1-s intervals. All mea-
surements were made at 25 °C. The contact angle was
calculated for each image using a Young–Laplace curve
fit using the CAM 200 image analysis software, and
resulting right and left contact angles were averaged. A
minimum of five repeat measurements were made for
each material using separate glass slides.
Statistical analysis
Statistical analyses were performed using GraphPad
Prism 6 software. Data sets were tested for normality
and suitable tests of comparisons were subsequently
chosen. All values were reported as mean value ± SD,
unless stated otherwise. Data were analysed by one-way
or two-way analysis of variance (ANOVA) with
Dunnett’s post-hoc test, unless otherwise stated. p ≤ 0.05
was considered significant.
Results
The first part of this study determined whether the initial
cell seeding density influenced differentiation capacity.
Previously, we showed that the ejection rate affected the
cell dose delivered and that cell recovery was negatively
impacted by low ejection flow rates [28, 29]. Thus, it was
critical to quantitatively assess the impact of the cell dose
delivered upon the differentiation capacity. The second
part of the study assessed the impact of varying ejection
rate on the differentiation behaviour of ejected cells.
Lastly, biomaterial-based formulations were selected as
candidate biomimetic carriers to maximise hMSC recov-
ery at low ejection rates and investigate the differentiation
behaviour of ejected cells.
Impact of initial cell seeding density on differentiation
potential of hMSCs
Hydroxyapatite deposition was used as a marker of
osteogenic differentiation of hMSCs. Additional file 2:
Figure S2A, B shows no significant difference in
osteogenic differentiation between the various cell num-
bers seeded initially, as shown by amounts of hydroxy-
apatite deposited and normalised mineral deposition to
cell number (p < 0.05). All cell densities exhibited similar
final cell numbers at day 21, with lower initial cell seed-
ing densities exhibiting a significantly higher fold change
in cell number relative to day 0 (p < 0.05) when
expressed as fold change in cell number relative to the
number of cells initially seeded (Additional file 2: Figure
S2C). There was no significant difference in the osteo-
genic differentiation of different cell seeding densities, as
shown by fluorescence microscopy images of hydroxy-
apatite bone nodules (Additional file 2: Figure S2D).
In contrast to this, there was a clear correlation be-
tween initial seeding density and adipogenesis, as shown
by AdipoRed™ staining and statistically significant differ-
ences in normalised fluorescence data relative to the full
seeding density of 7 × 105 cells per well (p < 0.05;
Additional file 3: Figure S3A, B). The dependence of adi-
pogenesis on initial cell seeding density is also shown in
Additional file 3: Figure S3C, where fluorescence mi-
croscopy images demonstrate an increasing intensity of
fluorescent staining of intracellular lipids with increasing
initial cell seeding numbers.
The study therefore focused on osteogenesis for subse-
quent studies as a model of differentiation to investigate
the impact of ejection rate on differentiation of ejected
hMSCs, since mineralisation at day 21 was shown to be
independent of the initial cell seeding density.
Ejection rate influenced osteogenic differentiation of
ejected hMSCs
Directly plated control and ejected samples showed
mixed populations of both adipocytes and osteoblasts.
Samples ejected at 10 μl/min exhibited visibly less cells
exhibiting the adipocyte morphology compared to other
samples. In addition, brighter OsteoImage™ staining of
hydroxyapatite (HA) was evident in the samples ejected
at 10 μl/min relative to directly plated controls and
other ejected samples (Fig. 1a). All ejected samples gave
similar absolute fluorescence values when stained with
OsteoImage™ (Fig. 1b); samples ejected at 10 μl/min ex-
hibited lower cell numbers at day 21 relative to the con-
trol (Fig. 1c). However, samples ejected at 10 μl/min
exhibited statistically significant higher normalised fluor-
escence values (Fig. 1d), compared to the directly plated
control at 21 days (p < 0.05).
Biomaterial-based delivery systems enhanced cell dose
recovery and viability
As retention in the delivery device and shear stress may
result in a lower number of viable cells delivered, it was
hypothesised that co-injecting cells with biomaterial-
based carriers may improve recovery. Collagen type I,
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gelatin, bone decellularised ECM (bECM) and high-
viscosity CMC were selected to test this hypothesis.
Incorporating cells in a protective viscous medium
improved cell delivery (Fig. 2a). Cells suspended within
2% gelatin type B exhibited the best recovery, with a sig-
nificantly improved percentage of viable cells of 87.5 ±
14.1% compared to 32.1 ± 19.1% of the dose delivered
when ejected with PBS. Relative to gelatin and CMC, de-
livery with collagen and bECM provided significantly
lower percentages of viable cells, with 53.4 ± 24.4% and
60.7 ± 10.1% respectively delivered. To investigate the
effect of using a lower concentration of the same mater-
ial, two concentrations of CMC (0.5% and 0.25% (w/v))
were compared (Fig. 2b). The lower concentration (0.25%
(w/v)) of CMC resulted in a significantly lower percentage
of the dose being delivered as viable cells (p = 0.05).
Live/Dead staining revealed a high proportion of viable
cells among all cell carriers investigated (Fig. 2c). How-
ever, a visibly lower number of cells appeared in ejected
samples suspended in PBS compared with other carriers.
Bright-field images of the ejected samples 24 h post ejec-
tion (Fig. 2d) displayed an obvious presence of fibril-like
structures in samples ejected within collagen and bECM;
cells ejected within other carriers did not display fibrillo-
genesis. These fibrils were not stained by calcein (Fig. 2c).
The proliferative ability of ejected hMSCs was not sig-
nificantly affected by choice of cell carrier, with similar
fold changes in cell numbers observed at day 10 relative
to the control (Fig. 2e).
Characterisation of biomaterial-based carriers
The rheological properties and surface tension of the
carriers were characterised to elucidate the effects of
material properties upon cell behaviour. Gelatin dis-
played the lowest viscosity (0.01 ± 0.0007 Pa.s) and colla-
gen the highest (0.66 ± 0.11 Pa.s) (Fig. 3a). The steady
shear rheological properties of the carriers are presented
in Fig. 3b. bECM, gelatin and collagen showed more sig-
nificant shear-thinning profiles (Δη ~ 104 Pa.s) than both
concentrations of CMC (Δη ~ 102 Pa.s). Collagen had a
viscosity of around 150 Pa.s at a shear rate of 0.01 s− 1,
shearing down to 0.001 Pa.s at 1000 s− 1. Gelatin exhib-
ited a viscosity of around 1 Pa.s at 0.01 s− 1, shearing
down to 0.002 Pa.s at a shear rate of 1000 s− 1 and not
crossing over the profiles of both CMC concentrations.
A viscometric three-step thixotropy test was carried out
to investigate recovery of material properties (Fig. 3c).
CMC and collagen showed fast and complete recovery
within seconds. Gelatin recovered its viscosity within a
few seconds to almost 90% of its initial value, but started
breaking down 70 s following strain removal. bECM
showed a more gradual recovery to almost 65% of its ori-
ginal properties at 180 s following strain removal. Due to
their shear-thinning and self-healing properties, all car-
riers investigated were shown to be injectable through a
clinically relevant 30G needle (Fig. 3d).
All cell carriers employed in this study, except CMC,
showed higher storage moduli than loss moduli, with
curves being parallel and almost linear, which confirmed
Fig. 1 Effect of ejection rate on osteogenic differentiation capacity of hMSCs ejected via 30G needles, cultured in bipotential osteogenic/
adipogenic media for 21 days. a Representative bright-field and fluorescence microscopic images showing ejected hMSCs after culturing in
bipotential media. Cell nuclei stained red (PI), mineralised areas stained green (OsteoImage™). Intracellular lipid accumulation indicated by
arrows (scale bar = 100 μm). b OsteoImage™ fluorescence values for ejected hMSCs at day 21. Each bar represents mean fluorescence values ± SD
(n = 9 in three independent experiments and two donors). c Number of cells at day 21 quantitated using PI staining of hMSCs from two donors
(mean ± SD, n = 6). d OsteoImage™ fluorescence readings normalised to cell count, based on PI staining (mean ± SD, n = 6). Statistically
significant difference from directly plated control using ANOVA and Dunnet’s post-hoc test: *p ≤ 0.05, ***p≤ 0.001. PI propidium iodide, RFU
relative fluorescence unit, Unind uninduced, Ctrl control
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Fig. 3 Rheological characterisation of biomaterial-based cell carriers employed in this study. a Viscosities of carriers determined at 25 °C with a
constant shear rate of 1 s− 1 (mean ± SD, n = 3). b Shear thinning properties of different carriers employed shown by steady shear rheological
measurements. c Viscometric three-step thixotropy test to display structure recovery of the hydrogel immediately after disruption due to a high-
magnitude shear-rate strain (10,000 s− 1), followed by a low-magnitude strain (1 s− 1) to monitor recovery of bulk properties. d CMC 0.5% ejected
through a 30G needle, representative of injectability of biomaterials investigated. CMC carboxymethyl cellulose, ECM extracellular matrix
Fig. 2 Cell recovery, viability and proliferation after ejecting hMSCs suspended in various carriers via 30G needles at 10 μl/min. a Proportion of hMSCs
delivered, measured using PrestoBlue™, within phosphate buffered saline (PBS), carboxymethyl cellulose (CMC), gelatin (Gel), type I collagen (Coll) and
bone extracellular matrix (bECM). Data represent averages from three donors in five independent experiments (n = 5, mean ± SD). Data normalised
against control value of directly plated cells. **p≤ 0.01, ****p≤ 0.0001, one-way ANOVA with Dunnett’s post-hoc test. b Percentage of cell dose
delivered as viable cells when ejected at 10 μl/min via 30G needles suspended within two concentrations of CMC (0.5% and 0.25%). Data represent
averages from two donors (n = 3, mean ± SD). Data normalised against control value of directly plated cells. Statistically significant differences between
numbers of ejected cells compared with control: *p = 0.05, one-way ANOVA with Kruskal–Wallis analysis. c Representative Live/Dead-stained
fluorescence images of hMSCs 24 h following ejection at 10 μl/min, using various biomaterials as cell carriers (scale bar = 100 μm). d Representative
bright-field images showing morphology of ejected hMSCs cultured for 24 h post ejection. Bundles of fibrils surrounding the ejected cells depicted
by arrows (scale bar = 50 μm). e Proliferation of hMSCs given as fold change in number from day 1 of each sample, measured using PrestoBlue™
(mean ± SD, n = 4 measured in two donors). Ctrl control
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their hydrogel nature. However, CMC displayed a higher
G′′ than G′, and should therefore be classified as a
viscous carrier or viscosity modifying excipient. All
carriers displayed broad linear viscoelastic regions
(Additional file 4: Figure S4). Collagen and bECM exhib-
ited failure of the gel structure at high strains of around
65% and demonstrated strain stiffening behaviour.
All biomaterials exhibited water contact angles ranging
from 18° to 35° (Fig. 4a). PBS, collagen and bECM were
the most hydrophilic; PBS had the lowest contact angle
of 18.6 ± 3.0°, while collagen was less hydrophilic with a
contact angle of 24.0 ± 2.7°. Gelatin was the least hydro-
philic among the biomaterials investigated, with a con-
tact angle of 34.3 ± 5.0° (Fig. 4b). The more dilute
concentration (0.25%) of CMC exhibited a lower contact
angle of 29.0 ± 5.8°, compared to 33.4 ± 4.1° for the
higher concentration of 0.5% (Fig. 4c).
Impact of biomaterial-based cell carriers upon differentiation
capacity of hMSCs
All directly plated control and ejected hMSCs under-
went osteogenic differentiation after 21 days of culture
in bipotential medium (Fig. 5). All samples exhibited a
mixed population of cells displaying typical adipocyte
morphology as well as mineralised bone nodules. PBS-
ejected samples consistently displayed visibly lower
numbers of cells exhibiting adipocyte morphology, in
addition to some cells displaying a fibroblast-like morph-
ology typical of undifferentiated MSCs. Whilst fluores-
cence images indicated that all control and ejected
samples exhibited mineralisation, a notably higher extent
of calcium and hydroxyapatite deposition was observed
in samples ejected within collagen and bECM compared
to the control and other carriers. Quantitative assess-
ments of hydroxyapatite deposition (Fig. 6a) confirmed
that cells co-ejected within collagen, bECM and gelatin
led to significantly enhanced mineralised content relative
to samples ejected within PBS. However, all samples ex-
hibited no significant difference in normalised fluores-
cence values (Fig. 6b).
To determine whether ejection forces and biomaterial-
based delivery had a synergistic effect upon mineralisa-
tion, hydroxyapatite deposition was compared in cells
suspended within collagen and bECM, either directly
plated in 12-well plates (referred to as ‘plated’) or ejected
at 10 μl/min (‘ejected’). Samples were directly plated at
60% of the initially ejected cell number within each car-
rier material to account for the loss of cells during ejec-
tion and to preclude any potential influence of initial
seeding density (Fig. 2a). As shown in Fig. 6c, d, there
was no significant difference in hydroxyapatite depos-
ition between the directly plated and ejected cells within
collagen and bECM at day 21, in terms of both absolute
and normalised values.
To determine whether ALP was released into the
media as a result of shear stress exposure, culture media
were assayed following induction of differentiation. At
day 2, media ALP activity was generally higher in ejected
hMSCs compared to directly plated samples. Ejection
within PBS and bECM increased released ALP activity
compared with directly plated hMSCs (Fig. 6e, p < 0.05).
To determine whether ejection forces and biomaterial-
based carriers had a synergistic effect upon released
ALP, media ALP levels in plated versus ejected cells,
Fig. 4 Measurement of contact angles of biomaterial-based cell carriers on a glass surface. a Contact angle images of various biomaterials
employed on soda-lime glass slides measured at room temperature. b, c Measurement of contact angles of various carriers on a soda-lime glass
surface. Each bar represents mean ± SD (n = 5). **p < 0.01, ***p < 0.001, relative to PBS. PBS phosphate buffer saline, CMC carboxymethyl cellulose,
Coll collagen, ECM extracellular matrix
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Fig. 5 Representative bright-field and fluorescence microscopy images displaying qualitative assessment of osteogenic differentiation capacity of
hMSCs post ejection, after culturing in bipotential ‘mixed’ media for 21 days. To assess the degree and distribution of mineralisation of the ECM,
the last stage of osteogenesis, samples were observed using dissection and bright-field microscopy (10×), in addition to staining with Alizarin Red
S (10×) and OsteoImage™/PI (5×). Cells exhibiting typical adipocyte morphology depicted in bright-field microscopy images using arrows (scale
bars = 50 μm). Red represents calcium deposition stained using Alizarin Red, and green depicts hydroxyapatite nodules stained using OsteoImage™.
Ctrl control, PBS phosphate buffer saline, CMC carboxymethyl cellulose, ECM extracellular matrix, PI propidium iodide
Fig. 6 Impact of biomaterial-based carriers on osteogenic differentiation markers of hMSCs ejected via 30G needles, cultured in bipotential media
for 21 days. a OsteoImage™ fluorescence values, showing hydroxyapatite formation. Each bar represents mean fluorescence value ± SD, n = 6 in
three donors. Statistically significant difference relative to PBS using ANOVA and Dunnet’s post-hoc test: *p≤ 0.05, **p≤ 0.01. b OsteoImage™ fluorescence
intensity readings normalised to PI-based cell counts (mean ± SD, n = 6). c Ejected versus directly plated hMSCs, suspended within collagen and ECM,
assessed for osteogenic differentiation capacity. ‘Ejected’ cells were ejected at 10 μl/min, and ‘plated’ cells were 60% of ejected cell number directly plated
in 12-well plates. Results are mean fluorescence values ± SD, n = 4 in two donors. (d) OsteoImage™ fluorescence intensity readings in (c) normalised to
PI-based cell counts (mean ± SD, n = 4 in two donors). e Media alkaline phosphatase (ALP) activity levels of hMSCs ejected at 10 μl/min, via 30G needles,
cultured in bipotential osteogenic/adipogenic media for 2 days after adding differentiation media 24 h post ejection. Values shown are mean ± SD (n= 3
in two donors). Statistically significant differences in ALP levels relative to control (Friedman test with Dunn’s post-hoc test): *p< 0.05. f Released ALP levels
in ejected versus directly plated hMSCs suspended within collagen and ECM. ‘Ejected’ cells were ejected at 10 μl/min, and ‘plated’ cells were 60% of the
initially ejected cell number directly plated in 12-well plates. Results are mean fluorescence values ± SD (n = 4 in two donors). RFU relative fluorescence
unit, Ctrl control, PBS phosphate buffer saline, CMC carboxymethyl cellulose, ECM extracellular matrix, Coll collagen
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suspended within collagen or bECM, were compared.
Figure 6f shows increased media ALP levels in ejected
samples relative to plated ones within collagen and
bECM.
Although total cellular ALP activity was significantly
lower for hMSCs ejected within PBS than for control
samples at day 2 (Additional file 5: Figure S5A), normal-
ised levels of ALP production were similar for all sam-
ples tested at this time point (Additional file 5: Figure
S5B). Expression of normalised cellular ALP generally
peaked earlier (day 4) for directly plated samples com-
pared to ejected samples (day 7). To explore whether
shear forces contributed to ALP expression pattern, dir-
ectly plated and ejected hMSCs within bECM and colla-
gen carriers were compared. The same pattern of
normalised ALP levels peaking earlier (at day 4) in directly
plated samples relative to ejected samples was observed
(Additional file 5: Figure S5C), and no significant differ-
ences in DNA content (Additional file 5: Figure S5D).
After 21 days, immunostaining for osteocalcin (OCN)
showed a robust expression of this late osteogenic marker
across all samples after 21 days of culture (Additional file 5:
Figure S5E).
Discussion
Since previous work demonstrated that cell ejections
at slower flow rates resulted in lower percentages of
the cell dose being delivered [28, 29], experiments
were carried out first to investigate the dependence
of differentiation capacity on initial cell number using
bipotential media. In typical monopotential differenti-
ation media, two different variables may act to direct
hMSCs down a certain differentiation pathway:
biochemical-based induction or effects of exposure to
mechanical forces of ejection. Deducing the impact of
physical cues on cell differentiation fate is difficult to
explore within the chemically defined environments
of monopotential differentiation media. By using
‘mixed’ media, a bipotential setting was provided
whereby the appropriate chemical differentiation cues
required for both osteogenesis and adipogenesis were
available. This allowed us to study the impact of
physical cues, such as mechanical forces or cell car-
rier, on cell lineage fate independent of chemical dos-
ing variables.
Impact of cell seeding density on differentiation capacity
of hMSCs
No statistically significant differences were detected in
hydroxyapatite deposition at the initial seeding dens-
ities under investigation. Thus, we postulated that the
different initial cell seeding numbers resulting from
the various ejection rates tested had negligible effects
on mineralisation at day 21, even at the lowest flow
rate under investigation (~ 35% of cell dose is deliv-
ered at 10 μl/min [28]). These results are consistent
with findings from studies carried out on various
scaffolds, which demonstrated that higher seeding
densities do not necessarily produce enhanced prolif-
eration and differentiation [40, 41]. Holy et al. [42]
investigated the effect of initial seeding density upon
rat bone marrow-derived cell differentiation on PLGA
scaffolds and showed that final mineralised tissue for-
mation was independent of initial seeding density.
When cell numbers at day 21 were expressed as
fold change in cell number to initial cell seeding
number, it was found that lower seeding densities
corresponded to the highest proliferation, which
agrees with previous studies by McBeath et al. [43].
In contrast to the effect on the osteogenesis marker
quantified, the adipogenic differentiation capacity was
influenced by cell seeding number. This result is in
line with previous findings [43, 44]. As mineralisation
at day 21 was shown to be independent of initial cell
seeding density, osteogenesis was selected as the
model for this study. Osteogenesis is a robust, well-
established in-vitro cellular model of differentiation in
hMSCs with well-defined assays and measurable out-
puts [45].
Ejection rate influenced osteogenic differentiation
capacity of ejected hMSCs
Since we established that the different cell numbers
ejected at different rates did not influence total mineral-
isation levels nor normalised mineralisation-to-cell-num-
ber values at day 21, we moved on to investigate the
impact of ejection rate on the osteogenic differentiation
capacity of ejected hMSCs.
Exposure of MSCs to shear stress, whether controlled
(fluid flow) or uncontrolled (flow perfusion), has been
reported to result in enhanced osteogenic matrix
production and maturation [46–48]. Previous work has
qualitatively demonstrated that MSCs ejected at 10 μl/min
resulted in considerably lower osteogenic differentiation
capacity [28], but no further investigation was carried out.
Normalised mineralisation values of cells growing in the
bipotential differentiation environment showed a signifi-
cantly higher level of mineral deposition per cell at the
lowest flow rate (10 μl/min) relative to control (Fig. 1b).
This suggests that hMSCs ejected at this rate either prefer-
entially underwent osteogenic differentiation relative to
the other samples, started differentiating earlier or had en-
hanced osteogenic efficiency per cell. These differentiation
trends confirmed that prolonged exposure to the mechan-
ical forces generated at 10 μl/min, rather than cell density
and associated cell–cell interactions, influenced the differ-
entiation fate of ejected cells.
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Biomaterial-assisted delivery
The development and evaluation of convenient, cost-
effective and efficient cell delivery systems will aid the
translation of cell-based therapies to the clinic. This
study explored whether the use of naturally derived bio-
materials will influence cellular differentiation and po-
tentially stimulate endogenous regeneration, acting as
instructive cell delivery platforms. This study investi-
gated the effects of using various natural biomaterial-
based cell carriers for ejection of hMSCs on cell dose
recovery, commitment and differentiation capacity in a
clinically relevant syringe/needle ejection scenario. The
choice of biomaterials reflects our aim to achieve simple,
reproducible and clinically relevant delivery of hMSCs to
facilitate low-dosage cell therapies.
Since there are unavoidable delays in any clinical cell
delivery procedure, cell carriers may provide physical
and chemical cues within this time that would inevitably
direct cell functionality outcomes, such as proliferation
and differentiation. Within biomaterials, cues may in-
clude material composition as well as external physical
cues resulting from the exposure of cells to mechanical
forces associated with injection procedures. Materials
utilised in this study were chosen to be readily available,
customisable, user-friendly and easily injectable through
clinically relevant needles. Since ECM, composed mainly
of proteoglycans, glycosaminoglycans and fibrous pro-
teins (e.g. collagen), provides key biochemical and bio-
mechanical cues required for tissue differentiation and
homeostasis [49], materials were also selected based on
major components of the ECM. Protein-based polymers
have the advantage of mimicking characteristics of the
natural ECM, and thereby the potential to impact the
growth and organisation of transplanted cells [24].
Collagen type I, for example, has been widely applied as
scaffolds for cell delivery, including animal models of
brain injury, with good biocompatibility [50, 51]. Simi-
larly, gelatin is a hydrolysed form of collagen [52] with
biomechanical similarity to the ECM [53]. The supple-
mentation of algal cultures with CMC, as a modifier of
interfacial properties, has been reported to protect algal
cells against hydrodynamic stress [54].
Results revealed that utilising injectable hydrogels and
viscosity modifying excipients for cellular delivery dem-
onstrated positive effects on cell recovery (Fig. 2). A sig-
nificant loss of cells at 10 μl/min was observed in
unprotected (PBS) samples at 24 h post ejection. Gelatin
(protein-based) and CMC (polysaccharide-based) cell
carriers displayed the highest percentage of viable cells
delivered, with no significant difference to directly plated
samples. In comparison, collagen and bECM carriers
(both protein based) resulted in lower cell recovery, yet
were significantly better than ejecting within PBS. An
improvement in cell viability post ejection was obtained
previously by Aguado et al. [10] using alginate gels via a
28G needle, which had been suggested to be due to plug
flow, whereby the hydrogel adjacent to the walls under-
goes shear thinning and forms a fluid layer which acts as
a lubricant [55]. This lubricating fluid layer may be one
explanation for the higher percentages of the cell doses
delivered in this study through keeping the cells in the
central plug zone away from the walls. The significant
improvement in cell dose recovery demonstrated herein,
in clinically relevant narrow-bore needles at low ejection
rates used in clinical trials [35, 56], may be vital to cells
that display biological changes after exposure to mech-
anical forces.
Live/Dead staining confirmed that all tested carriers
conserved a high degree of viability of ejected cells. Mi-
croscopy revealed a dilute meshwork of what appears to
be collagen fibrils dispersed between cells in samples
ejected within collagen and bECM, since they were not
stained by calcein. Solubilised collagen I can be mixed
with living cells during gelation to implant cells in a
fibrillar collagen matrix. The force generation and prop-
erties of collagen fibrils are comparable to biological fila-
ments, such as actin or microtubules [57]. Non-covalent
inter-fibril network interconnections have been reported
to transmit cellular traction forces [58]. This may have
given rise to extracellular cues that affected cell fate in
samples ejected within collagen and bECM relative to
hMSCs ejected within PBS. Co-delivery of the cells
within the biomaterials studied showed that cells
remained viable in vitro 10 days post ejection.
Cell dose recovery did not correlate with the biochem-
ical nature of the polymer (protein-based versus
polysaccharide-based), so rheological studies were carried
out to investigate possible correlation of cell recovery with
mechanical properties of the biomaterials. Shear-thinning
behaviour of these biomaterials, showing a relatively large
change in the viscosity (Δη ~ 102–104 Pa.s) from low
(0.01 s− 1) to high (1000 s− 1) shear rates, is a beneficial
property for injection-based delivery through narrow-bore
needles. Viscometric thixotropy testing revealed that
biomaterials were able to recover after shearing, with
some biomaterials (collagen and CMC) exhibiting more
complete recovery than others. Oscillatory shear rheology
of the biomaterials also showed that some of the softer
materials with lower storage moduli (G′), such as CMC
and gelatin, resulted in better cell recovery than collagen,
which has a storage modulus that is 10-fold higher. How-
ever, rheological data were not sufficient to explain the
significant improvement of cell recovery with gelatin and
CMC carriers relative to collagen and bECM. Gelatin and
0.25% CMC, for example, displayed similar storage moduli
(Additional file 4: Figure S4), yet showed significantly dif-
ferent cell dose recovery rates. In addition, viscosities and
shear-thinning profiles of the two concentrations of CMC
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under investigation (0.5 and 0.25%) were not significantly
different, thereby not explaining the significant difference
in dose recovery between them. Therefore, focusing on
the rheological properties of a carrier to determine its effi-
cacy at delivering the required number of viable cells is
not sufficient.
Surface wettability can influence protein adsorption and,
in turn, initial cell attachment. Gelatin resulted in high
contact angles on glass despite being structurally similar
to collagen due to the preferred orientation of hydropho-
bic moieties at the air–gel interface, causing a specific ar-
rangement of water molecules [59]. Cell adhesion is
similar to physical adhesion in that the cell membrane
must make close molecular contact with the surface [60],
and therefore we hypothesised that greater levels of cell at-
tachment occurred with surfaces of high wettability since
cells can make close contact with these surfaces. Some
studies have shown that hydrophilic surfaces produced a
significant increase in the amount of protein adsorption, a
high initial rate of cell attachment [61, 62] and generally
better cell adhesion [63]. It has also been reported that
cells adhered and proliferated more on surfaces with mod-
erate hydrophilicity than on the more hydrophobic or
hydrophilic spots [64]. Improvement of cell attachment
with decreasing contact angles has been observed at incu-
bation times of up to 60 min [62]. The cell carriers with
the lowest glass surface wettability in this study displayed
the best cell dose recovery. This may be due to the lower
contact that these carriers provide with the glass surface
of the syringe, discouraging adhesion during the time
spent in the delivery device.
Cell recovery trends appeared to correlate with the
contact angles displayed by the various carriers, whereby
materials displaying the highest contact angles also dis-
played the highest percentage of cell dose recovered
(Figs. 2a and 4b). Moreover, cell recovery did not appear
to correlate with the shear-thinning properties of the
biomaterials under investigation, as suggested by previ-
ous studies [10, 55]. Collagen, for example, showed the
best shear-thinning properties yet the lowest percentage
of cell dose recovery between the biomaterials tested.
The ability of cells to attach to a surface will depend on
the cell type and surface used. Further experiments com-
paring the attachment of different cell types, syringe ma-
terial surfaces and a wider range of surface wettability
values are required to determine the generality of this
observation and make use of it to design more efficient
cell delivery systems.
A cell’s fate is tightly regulated by its microenviron-
ment, since cells commit to their fate by deriving infor-
mation from their surroundings [65]. ECM proteins are
recognised by cell surface receptors and are involved in
cell processes such as proliferation and differentiation.
For example, hyaluronan (HA), a naturally occurring
polysaccharide found in the ECM of the central nervous
system (CNS), can interact with various HA receptors
present on diverse cell types to promote cell adhesion
and survival [66]. Therefore, it was hypothesised that
biomimetic protein-based cell carriers may have a dis-
cernible impact on cell commitment and differentiation
capacity. Late-stage osteogenic differentiation was
enhanced by the protein-based cell carriers, namely col-
lagen, bECM and gelatin, as demonstrated by the min-
eralisation results. The higher mineralisation levels in
samples ejected within collagen (p < 0.01) compared to
control samples at day 21 suggested that the use of a
biomimetic cell carrier for the desired cell type can
enhance differentiation response significantly. Fibril-
forming collagen type I forms more than 90% of the
organic mass of bone [67]. Bone marrow MSCs have
been reported to undergo osteogenesis when cultured
on collagen I matrices in vitro by interaction with the
COL-I-binding integrin α2β1 [68]. One study hypothe-
sised that adhesion to ECM proteins, in the absence of
soluble osteogenic stimulants, can act as insoluble cues
of osteogenesis [69]. Given the tissue specificity of ECM
and the abundant presence of collagen in bone-derived
ECM [70], these protein-based biomaterials have the po-
tential of mimicking native bone microenvironment pre
injection and closely mirror the target site once injected
[71]. Since a bipotential differentiation environment was
used in this study, it could be hypothesised that overall
mineralisation was enhanced due to a higher number of
cells being directed towards an osteogenic lineage, such
as in ECM (high total mineralisation but similar normal-
ised mineralisation levels per cell), and on a ‘mineralisa-
tion per cell’ basis in the case of PBS (low total
mineralisation but trending towards higher normalised
mineralisation levels relative to control). There was no
significant difference in hydroxyapatite deposition be-
tween directly plated and ejected cells within collagen
and bECM at day 21, suggesting that the more extensive
mineralisation observed with these carriers relative to
PBS is not augmented by mechanical forces encountered
by the cells during ejection.
ALP is widely used as an indicator of osteogenic com-
mitment, and commonly precedes bone matrix mineral-
isation [72, 73]. Significantly higher levels of ALP
released into the media were observed in the unpro-
tected samples ejected within PBS relative to directly
plated ones. There was also a notable trend of increased
media ALP levels in ejected samples relative to directly
plated ones within the same bECM carrier. A similar re-
sult was previously obtained by Yourek et al. [74],
whereby 24-h exposure to shear stress resulted in higher
ALP activity in the media than in control cells. Results
of cellular ALP analysis may be due to mechanical forces
caused by the ejection process, resulting in the slower
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commitment of ejected cells towards the osteogenic
lineage in vitro (in comparison to direct plating), but
stronger osteogenic expression. This is implied by later
peaking of normalised ALP expression in ejected sam-
ples at day 7, and enhanced mineralisation results with
cells ejected within protein-based carriers at day 21. Re-
sults suggest that although shear stress in combination
with collagen-based carriers supported osteogenic differ-
entiation more effectively relative to the plated control,
the commitment process took longer. Correspondingly,
Grellier et al. [75] exposed hMSCs to short periods of
fluid shear stress and showed that 30-min exposure up-
regulated ALP mRNA but 90-min exposure decreased it
to almost basal levels. Moreover, MSCs exposed to oscil-
latory fluid flow displayed reduced ALP activity despite
upregulating OCN mRNA under the same conditions
[76]. Osteogenic differentiation is complex and multifac-
torial, and the detailed mechanism of how ALP acts is
unclear [77]. Further studies are needed to explore the
impact on differentiation in more detail, since it is rea-
sonable to believe that injectable delivery may impair
cells’ ability to differentiate into the required cell type, or
cause differentiation into other undesirable cell types.
Conclusions
This study demonstrated that the use of natural, low-
viscosity biomaterials as cell carriers is an efficient ap-
proach to significantly improve the percentage of the cell
dose delivered relative to the commonly used saline cell
vehicle, enabling the administration of low-dosage cell
therapies through narrow, clinically relevant needles.
This improvement in cell dose recovery was not associ-
ated with the rheological properties of the biomaterials
utilised, as had been suggested by previous studies.
Moreover, the extent of differentiation in hMSCs, as
demonstrated through the use of osteogenesis as a
model of stem cell differentiation, was shown to be sub-
stantially altered by the selection of biomaterial carrier,
despite limited contact time of the carrier with ejected
cells during delivery, as well as ejection rate. The devel-
opment of tailored biomaterial-assisted cell delivery sys-
tems for the desired application will accelerate clinical
translation of cell-based therapeutics and allow the util-
isation of biomaterials for more efficient cell delivery
and potentially directing stem cell fate.
Additional files
Additional file 1: Figure S1. Showing schematic presentation of
methodology used to explore effects of various cell carriers on hMSC
delivery. Efficacy of delivery, in terms of cell recovery, viability and
proliferation capacity, was assessed. In addition, various parameters of
osteogenic differentiation were measured to determine the potential
impact of various cell carriers on osteogenic differentiation capacity.
(PDF 160 kb)
Additional file 2: Figure S2. Showing effect of initial cell seeding
density of hMSCs on their osteogenic differentiation potential when
cultured in bipotential adipogenic/osteogenic media, quantified based
on mineral deposition. (A) OsteoImage™ staining for hydroxyapatite in
hMSCs from two donors seeded at different initial seeding densities in a
12-well plate, cultured in bipotential media for 21 days (mean ± SD;
n = 6). No significant difference revealed between various initial cell
seeding densities, analysed using one-way ANOVA and Tukey’s post-hoc
test. ns no significant difference. (B) OsteoImage™ fluorescence readings
normalised to cell count, based on nuclear staining using PI (mean ± SD,
n = 4). Statistical analysis performed using Kruskal–Wallis test with Dunn’s
post-hoc test. (C) PI cell counts normalised to respective initial cell
numbers seeded, expressed as fold change relative to initial cell seeding
density (mean ± SD, n = 4). Data represent averages from two donors.
Statistically significant difference from full seeding density of 70,000 cells/
well: *p < 0.05, Kruskal–Wallis test with Dunn’s post-hoc test. (D) Representative
fluorescence microscopy images of hMSCs at day 21. Nuclei stained with PI,
and hydroxyapatite stained fluorescently using OsteoImage™
(scale bar = 100 μm). (PDF 1007 kb)
Additional file 3: Figure S3. Showing effect of initial cell seeding
density of hMSCs on their adipogenic differentiation when cultured in
bipotential adipogenic/osteogenic media. (A) AdipoRed™ staining for
lipid content in hMSCs seeded at different initial seeding densities in a
12-well plate, cultured in bipotential media for 21 days (n = 4). Statistically
significant difference from the full seeding density of 70,000 cells/well:
**p < 0.01, *p < 0.05, Kruskal–Wallis test with Dunn’s post-hoc test.
(B) AdipoRed™ fluorescence readings, adjusted for cellular count based
on nuclear staining using Hoechst 33,258 (mean ± SD, n = 3 in triplicates).
Statistical analysis performed using Kruskal–Wallis test with Dunn’s
post-hoc test. *p < 0.05. (C) Fluorescence microscopy images of hMSCs
cultured in bipotential differentiation media at day 21. Lipid droplets
stained fluorescently using AdipoRed™ Adipogenesis Reagent, after
which nuclei were counterstained with Hoechst (scale bar = 100 μm).
(PDF 610 kb)
Additional file 4: Figure S4. Showing oscillatory rheological
measurements of biomaterial-based carriers to obtain storage (G′) and
loss (G″) moduli from a strain-amplitude sweep (0.1–1000%) performed at
6 rad/s (n ≥ 3). Carried out for (A) 5 (0.5%) and 2.5 (0.25%) mg/ml CMC,
(B) 20 mg/ml (2%) gelatin, (C) 1.75 mg/ml collagen and (D) 1.75 mg/ml
bone ECM. (PDF 153 kb)
Additional file 5: Figure S5. Showing cellular ALP activity levels of
hMSCs at different time points following ejection at 10 μl/min via 30G
needles, and cultured in bipotential media. (A) Cellular ALP analysed 2, 4
and 7 days post induction. Values are mean ± SD (n = 3 in two donors).
Statistically significant differences in ALP levels relative to control
(Friedman test with Dunn’s post-hoc test: *p < 0.05. (B) Cellular ALP
values normalised to DNA content (mean ± SD, n = 3 in two donors).
(C) Normalised cellular ALP levels in ejected versus directly plated hMSCs
suspended within collagen and ECM. ‘Ejected’ cells ejected at 10 μl/min,
and ‘plated’ cells were 60% of the initial cell number directly plated
(mean ± SD, n = 3 in two donors). (D) DNA content of hMSCs in ejected
versus directly plated samples suspended within collagen and ECM
(mean ± SD). (E) Representative immunofluorescent staining of human
osteocalcin (OCN) and nuclei counterstained with DAPI (blue) to confirm
osteogenic differentiation of hMSCs. Directly plated and ejected hMSCs
(via 30G needles at 10 μl/min) cultured in bipotential media at 21 days
post induction (scale bar = 50 μm). (PDF 926 kb)
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